Pharma Co. Secures New Drug Licensing Deals
Research Report

Knight Therapeutics Inc. (GUD:TSX; KHTRF:OTCMKTS) has raised its Canadian franchise sales and added to its CNS therapeutic area, according to a January 25 Research Capital note by analysts Dr. Andre Uddin and Seungwoo (Steve) Lee.

New Licensing Deals

The report stated that Knight Therapeutics signed an exclusive licensing deal with Amneal Pharmaceuticals to pursue regulatory approval and eventually market Amneal's IPX203 drug for Parkinson's disease in Canada and Latin America. IPX203 is a new oral extended-release capsule that delivers a combination of carbidopa and levodopa. 

Uddin and Lee also mentioned that on December 19, Knight Therapeutics had signed an exclusive licensing deal with Supernus Pharmaceuticals for the rights to develop and market Supernus's drug Qelbree for Attention-Deficit Hyperactivity Disorder (ADHD) in Canada. Qelbree is an extended-release formulation containing viloxazine, a compound that modulates serotonin and norepinephrine activity in the brain.

The report also touched on Knight's acquisition of Exelon, saying it is a part of Knight's diversified profile, but did not provide further details. 

Primed for Future Business

According to the report, Knight had a strong cash position in quarter three of 2023. This included $142 million in cash and $75 million in debt. The analysts noted that with this position, they believe Knight may be printed for future business development. 

"With the ongoing share buyback program and expansion of multiple portfolio assets, especially in the Latin American markets, we remain bullish and are maintaining our Buy rating and target price of $6.50," the analysts said.

Important Disclosures:

1. [COMPANY] is a billboard sponsor of Streetwise Reports and pays SWR a monthly sponsorship fee between US$4,000 and US$5,000. In addition, [COMPANY] has a consulting relationship with an affiliate of Streetwise Reports, and pays a monthly consulting fee between US$8,000 and US$20,000. Street Smart is conducting a digital media marketing campaign for this article on behalf of [COMPANY], and the company has paid a marketing fee between US$10,000 and US$100,000, of which Street Smart may receive 10-25% as compensation.
2. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of [COMPANY].
3. [PERSON_NAME] wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor/employee. He/she or members of his/her household own securities of: [COMPANY]. He/she or members of his/her household are paid by the following: [COMPANY]. His/her company has a financial relationship with the following companies: [COMPANY].
4.  This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
5. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.